Abstract
Background/Aim. Chronic kidney disease (CKD) is a global health concern
associated with increased cardiovascular risks and premature mortality.
Proteinuria is a vital prognostic indicator for CKD outcomes. Sodium-glucose
cotransporter 2 (SGLT2) inhibitors show promise in reducing proteinuria and
slowing CKD progression. The aim of the study was to investigate the impact
of SGLT2 inhibitor therapy on CKD patients over one year, evaluating serum
creatinine (sCr), 24-hour urine protein (24hPiU), estimated glomerular
filtration rate (eGFR), and blood pressure changes. Methods. This
prospective study monitored 79 CKD patients on therapy with SGLT2
inhibitors. Patients received an SGLT2 inhibitor (dapagliflozin) once daily
(10 mg), and assessments were conducted at baseline, 6 months and 1 year.
The study evaluated sCr, 24hPiU, eGFR, systolic blood pressure (BPs),
diastolic blood pressure (BPd), uric acid (UA), total cholesterol (TC),
triglycerides (TG), low-density lipoprotein cholesterol (LDL), sodium (Na+),
and potassium (K+). Results. Over the one-year follow-up, significant
changes were seen in UA levels (5.36 ? 4.99 ? 4.94 mg/dL; p=0.032), 24hPiU
(662.60 ? 574.11 ? 507.72 mg/dL; p=0.026), as well as BPs (128.44 ? 125.64 ?
126.12 mmHg ; p=0.028). No significant variations were observed in BPd, sCr,
TC, TG, LDL, K levels. Na+ levels displayed anotable decrease (148.21 ?
147.57 ? 146.41 mmol/L; p=0.021). Conclusion. The study suggests potential
benefits of SGLT2 inhibitors in managing CKD.
Publisher
National Library of Serbia